Abbott Laboratories (ABT) Total Debt (2009 - 2026)

Abbott Laboratories has disclosed Total Debt across 18 years of filings, most recently posting $34.0 billion for Q1 2026.

• Total Debt for Q1 2026 came in at $34.0 billion, up 157.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $34.0 billion (up 157.11% YoY), and the FY2025 annual result was $12.9 billion, down 8.47% from the prior year.
• Total Debt came in at $34.0 billion for Q1 2026 at Abbott Laboratories, up from $12.9 billion in the prior quarter.
• In the past five years, Total Debt ranged from a high of $34.0 billion in Q1 2026 to a low of $12.9 billion in Q4 2025.
• The 5-year median for Total Debt is $15.0 billion (2024), against an average of $16.2 billion.
• Across the five-year window, Total Debt dropped 13.69% in 2024 and soared 157.11% in 2026, its largest moves.
• Abbott Laboratories' Total Debt stood at $16.8 billion in 2022, then decreased by 12.48% to $14.7 billion in 2023, then fell by 3.77% to $14.1 billion in 2024, then slipped by 8.47% to $12.9 billion in 2025, then jumped by 163.34% to $34.0 billion in 2026.
• The last three Total Debt figures came in at $34.0 billion (Q1 2026), $12.9 billion (Q4 2025), and $12.9 billion (Q3 2025), per Business Quant data.